What are the indications, dosing regimen, contraindications, and adverse effects of Qelbree (viloxazine) for attention‑deficit/hyperactivity disorder (ADHD)?

Qelbree (Viloxazine Extended-Release) for ADHD

Qelbree is an FDA-approved nonstimulant medication for ADHD in patients 6 years and older, including adults, offering a valuable alternative when stimulants are ineffective, not tolerated, or contraindicated. 1

Indications

Qelbree is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in:

• Pediatric patients 6 years and older
• Adults 1

This represents an important expansion of nonstimulant options beyond atomoxetine, guanfacine, and clonidine—the three nonstimulants traditionally discussed in major ADHD guidelines 2, 3. While established guidelines from 2019-2024 do not yet include viloxazine (as it was approved in 2021), it fills a critical gap as a selective norepinephrine reuptake inhibitor with serotonin modulatory properties 4.

Dosing Regimen

Pediatric Patients (6-11 years)

• Starting dose: 100 mg once daily
• Titration: Increase by 100 mg weekly as needed
• Maximum dose: 400 mg once daily 1

Adolescents (12-17 years)

• Starting dose: 200 mg once daily
• Titration: After 1 week, may increase by 200 mg
• Maximum dose: 400 mg once daily 1

Adults

• Starting dose: 200 mg once daily
• Titration: Increase by 200 mg weekly as needed
• Maximum dose: 600 mg once daily 1

Administration Details

• Take once daily with or without food
• Capsules may be swallowed whole OR opened and sprinkled on pudding (consume within 15 minutes) or applesauce (consume within 2 hours)
• Do not cut, crush, or chew capsules 1

Special Populations: Severe Renal Impairment

In patients with eGFR <30 mL/min/1.73m²:

• Starting dose: 100 mg once daily
• Titration: 50-100 mg weekly increments
• Maximum dose: 200 mg once daily
• No adjustment needed for mild-moderate renal impairment 1

Onset of Action

Clinical improvement typically occurs within 1-2 weeks, which is notably faster than atomoxetine's 4-week onset 5. In adult trials, treatment effects were significant by week 2 and sustained beyond 24 months 6, 7.

Contraindications

Absolute Contraindications

1. Concomitant MAOI use or within 14 days of discontinuing an MAOI
2. Concomitant use with sensitive CYP1A2 substrates or those with narrow therapeutic range 1

Critical pitfall: Viloxazine is a moderate CYP1A2 inhibitor. Avoid combining with drugs like theophylline, tizanidine, or duloxetine. Coadministration with moderate sensitive CYP1A2 substrates is not recommended; dose reduction may be warranted if unavoidable 1.

Warnings and Precautions

Black Box Warning: Suicidal Thoughts and Behaviors

In clinical studies, higher rates of suicidal ideation and behavior occurred in ADHD patients treated with Qelbree versus placebo. 1

Mandatory actions:

• Screen for personal/family history of suicide, bipolar disorder, and depression before initiating treatment
• Closely monitor all patients for clinical worsening and emergence of suicidal thoughts/behaviors
• This mirrors the black box warning on atomoxetine 2, 5

Cardiovascular Effects

• Assess heart rate and blood pressure before treatment, after dose increases, and periodically during therapy
• Monitor for increases in HR and BP (similar to atomoxetine's profile) 2, 1
• Obtain cardiac history including family history of sudden death, cardiovascular symptoms, Wolff-Parkinson-White syndrome, hypertrophic cardiomyopathy, and long QT syndrome
• If risk factors present, obtain ECG and consider cardiology referral before starting 2

Activation of Mania/Hypomania

• Screen patients for bipolar disorder before initiating treatment 1

Somnolence and Fatigue

• Advise patients to use caution when driving or operating machinery
• Somnolence (including sedation/lethargy) and fatigue are common 1

Adverse Effects

Most Common Adverse Events (≥5% and at least twice placebo rate)

Pediatric patients (6-17 years):

• Somnolence
• Decreased appetite
• Fatigue
• Nausea
• Vomiting
• Insomnia
• Irritability 1

Adult patients:

• Insomnia (14.8%)
• Headache
• Somnolence
• Fatigue (11.6%)
• Nausea (10.1%)
• Decreased appetite (10.1%)
• Dry mouth (9.0%)
• Constipation 1, 7

Discontinuation Rates

• Adverse event-related discontinuation <5% in pediatric trials 8
• 9.0% discontinuation rate in adults (vs 4.9% placebo) 7
• Generally well-tolerated with acceptable safety profile 6

Notable Safety Considerations

• No clinically significant cardiovascular or hepatic adverse effects observed 6
• Unlike atomoxetine, no reports of hepatitis (atomoxetine carries extremely rare hepatitis risk) 2
• No significant growth delays reported (unlike stimulants and atomoxetine which can affect growth) 2

Efficacy Data

Adolescents (12-17 years)

Phase 3 trials demonstrated statistically significant improvement in ADHD Rating Scale-5 Total scores:

• 200 mg/day: p=0.0232
• 400 mg/day: p=0.0091
• Improvements in both Inattention and Hyperactivity/Impulsivity subscales 8

Meta-analysis of adolescent data showed modest but consistent efficacy (Hedges' g = -0.33,95% CI -0.50 to -0.16) with no heterogeneity 9.

Adults

Phase 3 trial showed significant improvement in Adult ADHD Investigator Symptom Rating Scale (AISRS):

• Viloxazine ER: -15.5 ± 0.91 vs placebo: -11.7 ± 0.90 (p=0.0040)
• Significant improvements in executive function (BRIEF-A) 7

Comparative Context

Effect sizes are generally smaller than stimulants but comparable to atomoxetine 4, 5. However, the faster onset (1-2 weeks vs 4 weeks for atomoxetine) provides a clinical advantage 5.

Clinical Positioning

Use Qelbree when:

1. Stimulants are ineffective or cause intolerable side effects
2. Patient has contraindications to stimulants (e.g., substance use concerns, cardiovascular risk)
3. Patient/family prefers nonstimulant approach
4. Comorbid anxiety is present (though not specifically studied, serotonergic activity may be beneficial)

Advantages over atomoxetine:

• Faster onset of action (1-2 weeks vs 4 weeks)
• No reported hepatotoxicity
• Once-daily dosing with flexible administration (can sprinkle on food)

Compared to alpha-2 agonists (guanfacine/clonidine):

• No risk of rebound hypertension with abrupt discontinuation
• No bradycardia or hypotension concerns
• Different mechanism may benefit patients who don't respond to alpha-2 agonists 2

Monitoring Requirements

Before initiating:

• Cardiac history and family history screening
• Baseline heart rate and blood pressure
• Screen for suicidality, bipolar disorder, depression 1

During treatment:

• Monitor HR and BP after dose increases and periodically
• Assess for suicidal ideation/behavior at each visit
• Periodically reevaluate long-term need and adjust dose as needed 1

Key Clinical Pearls

• Viloxazine expands nonstimulant options beyond the three traditionally cited in major guidelines (atomoxetine, guanfacine, clonidine) 2, 3
• Faster onset than atomoxetine makes it particularly useful when timely symptom control is needed 5
• CYP1A2 interactions are critical—always check medication list before prescribing 1
• Flexible dosing formulation (can sprinkle on food) improves adherence in patients who cannot swallow pills 1
• No hepatic dose adjustment needed even in severe hepatic impairment, though elimination half-life increases 10